- Home
- CMP vs MLTX Comparison
CMP vs MLTX Comparison
Compare CMP & MLTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | CMP | MLTX |
|---|---|---|
| Founded | 1993 | 2021 |
| Country | United States | Switzerland |
| Employees | N/A | N/A |
| Industry | Other Metals and Minerals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.2B |
| IPO Year | 2003 | 2020 |
Fundamental Metrics
Financial Performance| Metric | CMP | MLTX |
|---|---|---|
| Price | $23.79 | $16.85 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 12 |
| Target Price | $21.50 | ★ $27.50 |
| AVG Volume (30 Days) | 503.6K | ★ 828.6K |
| Earning Date | 05-06-2026 | 05-11-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.43 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.25 | N/A |
| P/E Ratio | $54.28 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $8.60 | $5.95 |
| 52 Week High | $27.00 | $62.75 |
Technical Indicators
Market Signals| Indicator | CMP | MLTX |
|---|---|---|
| Relative Strength Index (RSI) | 52.79 | 47.55 |
| Support Level | $20.66 | $16.52 |
| Resistance Level | $25.80 | $19.03 |
| Average True Range (ATR) | 1.04 | 0.99 |
| MACD | 0.08 | 0.00 |
| Stochastic Oscillator | 67.73 | 32.28 |
Price Performance
Historical ComparisonAbout CMP Compass Minerals Intl Inc
Compass Minerals currently produces two primary products: salt and specialty potash fertilizer. The company's main assets include rock salt mines in Ontario, Louisiana, and the United Kingdom. The fertilizer is produced from a brine operation at the Great Salt Lake in Utah that produces sulfate of potash and magnesium chloride. Compass' salt products are used for deicing and also by industrial and consumer end markets. The firm's sulfate of potash is used by growers of high-value crops that are sensitive to standard potash.
About MLTX MoonLake Immunotherapeutics
MoonLake Immunotherapeutics is a clinical-stage biotechnology company advancing therapies to address unmet needs in inflammatory skin and joint diseases. The company is focused on the development of SLK, a novel tri-specific IL-17A and IL-17F inhibiting Nanobody that has the potential, based on response levels seen in clinical trials, to drive disease modification in dermatology and rheumatology patients. It is currently developing SLK in inflammatory diseases in dermatology and rheumatology where the pathophysiology is known to be driven by IL-17A and IL-17F.